Proteinuria and its consequences in renal disease.
Chronic renal diseases that involve proteinuria are typically characterized by an inexorable progression to end-stage renal failure. Many studies suggest that this progression may be the result of factors, such as intraglomerular hypertension and glomerular hypertrophy, that are unrelated to the initial disease. This paper reviews the mechanisms of progression of chronic renal diseases and discusses therapeutic strategies that should prevent or minimize further renal damage and the applicability of these strategies to patients with the rare X-linked lysosomal storage disorder Fabry disease. Renal involvement is a major feature of Fabry disease, which is characterized by vacuolated epithelial cells in the glomerulus and distal tubules, resulting from lipid inclusions within these cells. Although enzyme replacement therapy is the key strategy to halt the progression of Fabry disease, additional therapeutic options include blood pressure control, reduction of proteinuria, lipid control and inhibition of the renin-angiotensin system.


CONCLUSIONS
A range of therapeutic options, used in conjunction with enzyme replacement therapy, may have beneficial effects on the renal manifestations of Fabry disease.
Clinical Research Centre for Rare Diseases, Aldo e Cele Daccò, Ranica, Italy.
A
A
Schieppati
G
G
Remuzzi
D000804:Angiotensin II / Q000502:physiology; D002908:Chronic Disease; D018450:Disease Progression; D000795:Fabry Disease / Q000150:complications / Q000503:physiopathology*; D006801:Humans; D006949:Hyperlipidemias / Q000503:physiopathology; D006977:Hypertension, Renal / Q000503:physiopathology; D006984:Hypertrophy; D007674:Kidney Diseases / Q000188:drug therapy / Q000473:pathology / Q000503:physiopathology*; D007678:Kidney Glomerulus / Q000473:pathology; D011507:Proteinuria / Q000209:etiology / Q000503:physiopathology*
D000804:Angiotensin II